Ovoca Bio shares plummet after female libido treatment trial fails
31st Aug 2023 14:33
(Sharecast News) - Biopharmaceutical developer Ovoca Bio's shares were plummeting on Thursday, after it released a summary of the top-line results from its phase two dose-ranging study evaluating Orenetide.
Read moreOvoca Bio to dispose of Russian assets
8th Mar 2023 11:45
(Sharecast News) - Biopharmaceutical company Ovoca Bio announced on Wednesday that it will be disposing of certain Russian assets to the private Russian company Desirix.
Read moreOvoca Bio enrols participants in women's sexual drug trial
29th Jul 2022 16:00
(Sharecast News) - Women's health-focussed biopharmaceutical company Ovoca Bio announced the successful completion of participant enrollment in a phase 2 dose-ranging study assessing 'orenetide' on Friday.
Read moreOvoca Bio enrols first patient in sexual desire treatment trial
29th Jan 2021 11:15
(Sharecast News) - Biopharmaceutical company Ovoca Bio said on Friday that the first patient has been enrolled in a phase 2 dose-ranging study assessing 'BP-101', which it described as a novel treatment for premenopausal women with hypoactive sexual desire disorder (HSDD) - a condition characterised by a distressing lack or loss of sexual desire.
Read moreOvoca Bio appoints new chief business officer
9th Oct 2020 15:47
(Sharecast News) - Women's health-focussed biopharmaceuticals company Ovoca Bio announced the appointment of Christopher Wiltshire as its chief business officer and executive director of the board on Friday, effective immediately.
Read moreOvoca Bio hits stumbling block in Russia drug approval
2nd Oct 2020 10:10
(Sharecast News) - Biopharmaceutical company Ovoca Bio updated shareholders on Friday on its marketing authorisation application for BP-101, a novel synthetic peptide administered through a nasal spray, that was submitted to the Russian Ministry of Health (Minzdrav) in September 2019.
Read moreOvoca Bio narrows losses as BP-101 trials continue
16th Sep 2019 11:33
(Sharecast News) - Biopharmaceutical firm Ovoca Bio narrowed losses slightly in the first half of its trading year, while focus remained firmly on its continued development of a treatment for female sexual dysfunction.
Read moreOvoca Bio's IVIX ropes in Biorasi for development of 'Libicore' drug candidate
23rd Apr 2019 15:40
(Sharecast News) - Ovoca Bio announced on Tuesday that its subsidiary IVIX has begun the process of preparing an integrated clinical development plan for its investigational drug candidate, 'Libicore' (BP-101), for both the US and EU regions with US-based contract research organisation Biorasi.
Read more